SEONGNAM, South Korea, Dec. 23, 2025 /PRNewswire/ — SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) onSEONGNAM, South Korea, Dec. 23, 2025 /PRNewswire/ — SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on

SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug ‘SNB-101’ on Gastric Cancer.

2025/12/24 07:45
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

SEONGNAM, South Korea, Dec. 23, 2025 /PRNewswire/ — SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API: SN-38) which is a polymer nanoparticle drug under phase 1b/2 clinical trial for small cell lung cancer.

SNB-101 is the world’s first nanoparticle anticancer drug that has formulated extremely insoluble SN-38 into polymer nanoparticles, which is expected to significantly improve therapeutic efficacy and reduce side effects. It is currently undergoing active clinical development for various solid tumor indications in Korea, Europe, and the U.S.A.

Gastric cancer is classified as an extremely rare disease (with a prevalence <200,000) in the U.S. with a 5-year relative survival rate of only about 36% across all stages. Currently, the standard of care for advanced gastric cancer includes cytotoxic chemotherapy (such as irinotecan and paclitaxel) and targeted therapies like trastuzumab for HER2-positive patients. However, the prognosis for patients with advanced stages remains poor. Many patients eventually develop resistance to these first-line treatments or experience disease progression, leaving them with limited effective therapeutic options. According to SN Bioscience, SNB-101 showed excellent efficacy compared to existing standard of care treatments such as paclitaxel, irinotecan and trastuzumab in gastric cancer animal models.

Orphan drug designation is a program where the US FDA facilitates the development and approval of treatments for rare/incurable or life-threatening diseases. This designation provides the qualified drug developers with various benefits such as exclusive rights for 7 years from the date of marketing approval, tax credits for R&D costs, assistance for clinical trial design for clinical development, exemption from review application fees, and priority review support.

SNB-101 previously received ODDs from the US FDA for small cell lung cancer in July 2023 and pancreatic cancer in February 2024. By receiving an ODD for gastric cancer this time, SN Bioscience expects to gain momentum in indication expansion and clinical development.

About SN BioScience Inc.

SN BioScience is a biotech company established in May 2017. It is a drug delivery system R&D company specialized in anti-cancer drugs and is located in South Korea. SN BioScience was founded by pharmaceutical R&D experts, world-class bio-polymer research professors, and clinical professors. From the beginning of its establishment, it has focused on “commercialization” and has been developing nanoliposomes and nanoparticle drug carriers based on pharmacometrics and pharmacokinetics.

SNB-101

SNB-101 is an anticancer agent that is the world’s first nanoparticle formulation of the anticancer drug SN-38. It uses a delivery system sophisticatedly designed via dual nano-micelle technology which is a core platform technology of SN Bioscience. SN-38 is an active metabolite of irinotecan which is gaining attention for its use in antibody-drug conjugates (ADCs) such as Enhertu® and Trodelvy®. Compared to existing irinotecan products, drug resistance and safety have been significantly improved, and based on the animal studies, it is expected to be effective for lung cancer, pancreatic cancer, and stomach cancer, which were not the indications previously.

SNB-101 successfully completed Phase 1 clinical trials in patients with solid tumors (NCT04640480) and received IND approval for Phase 1b/2 from the US FDA in December 2024 for the treatment of small cell lung cancer. Subsequently, a regulatory protocol review is currently underway in Europe for phase 2 trials, which will evaluate both monotherapy and combination therapy in patients with small cell lung cancer.

Cision View original content:https://www.prnewswire.com/news-releases/sn-bioscience-received-us-fda-orphan-drug-designation-for-its-nano-anti-cancer-drug-snb-101-on-gastric-cancer-302649026.html

SOURCE SN BioScience Inc.

Market Opportunity
Talus Logo
Talus Price(US)
$0.00547
$0.00547$0.00547
-8.83%
USD
Talus (US) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Lovable AI’s Astonishing Rise: Anton Osika Reveals Startup Secrets at Bitcoin World Disrupt 2025

Lovable AI’s Astonishing Rise: Anton Osika Reveals Startup Secrets at Bitcoin World Disrupt 2025

BitcoinWorld Lovable AI’s Astonishing Rise: Anton Osika Reveals Startup Secrets at Bitcoin World Disrupt 2025 Are you ready to witness a phenomenon? The world of technology is abuzz with the incredible rise of Lovable AI, a startup that’s not just breaking records but rewriting the rulebook for rapid growth. Imagine creating powerful apps and websites just by speaking to an AI – that’s the magic Lovable brings to the masses. This groundbreaking approach has propelled the company into the spotlight, making it one of the fastest-growing software firms in history. And now, the visionary behind this sensation, co-founder and CEO Anton Osika, is set to share his invaluable insights on the Disrupt Stage at the highly anticipated Bitcoin World Disrupt 2025. If you’re a founder, investor, or tech enthusiast eager to understand the future of innovation, this is an event you cannot afford to miss. Lovable AI’s Meteoric Ascent: Redefining Software Creation In an era where digital transformation is paramount, Lovable AI has emerged as a true game-changer. Its core premise is deceptively simple yet profoundly impactful: democratize software creation. By enabling anyone to build applications and websites through intuitive AI conversations, Lovable is empowering the vast majority of individuals who lack coding skills to transform their ideas into tangible digital products. This mission has resonated globally, leading to unprecedented momentum. The numbers speak for themselves: Achieved an astonishing $100 million Annual Recurring Revenue (ARR) in less than a year. Successfully raised a $200 million Series A funding round, valuing the company at $1.8 billion, led by industry giant Accel. Is currently fielding unsolicited investor offers, pushing its valuation towards an incredible $4 billion. As industry reports suggest, investors are unequivocally “loving Lovable,” and it’s clear why. This isn’t just about impressive financial metrics; it’s about a company that has tapped into a fundamental need, offering a solution that is both innovative and accessible. The rapid scaling of Lovable AI provides a compelling case study for any entrepreneur aiming for similar exponential growth. The Visionary Behind the Hype: Anton Osika’s Journey to Innovation Every groundbreaking company has a driving force, and for Lovable, that force is co-founder and CEO Anton Osika. His journey is as fascinating as his company’s success. A physicist by training, Osika previously contributed to the cutting-edge research at CERN, the European Organization for Nuclear Research. This deep technical background, combined with his entrepreneurial spirit, has been instrumental in Lovable’s rapid ascent. Before Lovable, he honed his skills as a co-founder of Depict.ai and a Founding Engineer at Sana. Based in Stockholm, Osika has masterfully steered Lovable from a nascent idea to a global phenomenon in record time. His leadership embodies a unique blend of profound technical understanding and a keen, consumer-first vision. At Bitcoin World Disrupt 2025, attendees will have the rare opportunity to hear directly from Osika about what it truly takes to build a brand that not only scales at an incredible pace in a fiercely competitive market but also adeptly manages the intense cultural conversations that inevitably accompany such swift and significant success. His insights will be crucial for anyone looking to understand the dynamics of high-growth tech leadership. Unpacking Consumer Tech Innovation at Bitcoin World Disrupt 2025 The 20th anniversary of Bitcoin World is set to be marked by a truly special event: Bitcoin World Disrupt 2025. From October 27–29, Moscone West in San Francisco will transform into the epicenter of innovation, gathering over 10,000 founders, investors, and tech leaders. It’s the ideal platform to explore the future of consumer tech innovation, and Anton Osika’s presence on the Disrupt Stage is a highlight. His session will delve into how Lovable is not just participating in but actively shaping the next wave of consumer-facing technologies. Why is this session particularly relevant for those interested in the future of consumer experiences? Osika’s discussion will go beyond the superficial, offering a deep dive into the strategies that have allowed Lovable to carve out a unique category in a market long thought to be saturated. Attendees will gain a front-row seat to understanding how to identify unmet consumer needs, leverage advanced AI to meet those needs, and build a product that captivates users globally. The event itself promises a rich tapestry of ideas and networking opportunities: For Founders: Sharpen your pitch and connect with potential investors. For Investors: Discover the next breakout startup poised for massive growth. For Innovators: Claim your spot at the forefront of technological advancements. The insights shared regarding consumer tech innovation at this event will be invaluable for anyone looking to navigate the complexities and capitalize on the opportunities within this dynamic sector. Mastering Startup Growth Strategies: A Blueprint for the Future Lovable’s journey isn’t just another startup success story; it’s a meticulously crafted blueprint for effective startup growth strategies in the modern era. Anton Osika’s experience offers a rare glimpse into the practicalities of scaling a business at breakneck speed while maintaining product integrity and managing external pressures. For entrepreneurs and aspiring tech leaders, his talk will serve as a masterclass in several critical areas: Strategy Focus Key Takeaways from Lovable’s Journey Rapid Scaling How to build infrastructure and teams that support exponential user and revenue growth without compromising quality. Product-Market Fit Identifying a significant, underserved market (the 99% who can’t code) and developing a truly innovative solution (AI-powered app creation). Investor Relations Balancing intense investor interest and pressure with a steadfast focus on product development and long-term vision. Category Creation Carving out an entirely new niche by democratizing complex technologies, rather than competing in existing crowded markets. Understanding these startup growth strategies is essential for anyone aiming to build a resilient and impactful consumer experience. Osika’s session will provide actionable insights into how to replicate elements of Lovable’s success, offering guidance on navigating challenges from product development to market penetration and investor management. Conclusion: Seize the Future of Tech The story of Lovable, under the astute leadership of Anton Osika, is a testament to the power of innovative ideas meeting flawless execution. Their remarkable journey from concept to a multi-billion-dollar valuation in record time is a compelling narrative for anyone interested in the future of technology. By democratizing software creation through Lovable AI, they are not just building a company; they are fostering a new generation of creators. His appearance at Bitcoin World Disrupt 2025 is an unmissable opportunity to gain direct insights from a leader who is truly shaping the landscape of consumer tech innovation. Don’t miss this chance to learn about cutting-edge startup growth strategies and secure your front-row seat to the future. Register now and save up to $668 before Regular Bird rates end on September 26. To learn more about the latest AI market trends, explore our article on key developments shaping AI features. This post Lovable AI’s Astonishing Rise: Anton Osika Reveals Startup Secrets at Bitcoin World Disrupt 2025 first appeared on BitcoinWorld.
Share
Coinstats2025/09/17 23:40
Why Banks Restrict Accounts (And What Happens Next)

Why Banks Restrict Accounts (And What Happens Next)

In a world where most financial activity happens digitally, losing access to your bank account can feel sudden and stressful. One day everything works fine, and
Share
Techbullion2026/04/03 19:40
Trump's new AG immediately put on notice by GOP rep — and warned of 'criminal' liability

Trump's new AG immediately put on notice by GOP rep — and warned of 'criminal' liability

Moments after President Donald Trump fired Attorney General Pam Bondi, Deputy Attorney General Todd Blanche was elevated to her position and named acting attorney
Share
Rawstory2026/04/03 19:20

$30,000 in PRL + 15,000 USDT

$30,000 in PRL + 15,000 USDT$30,000 in PRL + 15,000 USDT

Deposit & trade PRL to boost your rewards!